Published in Rheumatol Int on November 27, 2008
Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol (2010) 0.85
Autoimmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus. Am J Physiol Endocrinol Metab (2012) 0.83
Why are kids with lupus at an increased risk of cardiovascular disease? Pediatr Nephrol (2015) 0.78
Update on cardiovascular disease in lupus. Curr Opin Rheumatol (2016) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum (1992) 14.73
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36
Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med (1991) 3.58
Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol (2001) 3.38
Systemic lupus erythematosus. Lancet (2007) 3.32
Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation (2001) 2.72
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum (1999) 2.36
Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res (2003) 1.94
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA (2000) 1.83
Vascular stiffness in women with systemic lupus erythematosus. Hypertension (2001) 1.68
Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 1.54
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol (1995) 1.52
Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol (1999) 1.37
'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) (2005) 1.33
Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med (1979) 1.29
Zinc deficiency causes oxidative damage to proteins, lipids and DNA in rat testes. J Nutr (1995) 1.24
Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol (2006) 1.23
Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol (2006) 1.16
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet (1996) 1.14
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev (2000) 1.09
High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum (2004) 0.95
Abnormal mechanical properties of larger arteries in postmenopausal women with systemic lupus erythematosus. Lupus (2004) 0.94
Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med (2004) 0.94
Biologic markers as predictors of cardiovascular disease. Am J Med (1998) 0.90
Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism (1998) 0.85
Anti-insulin antibodies and the natural autoimmune response in systemic lupus erythematosus. Lupus (2001) 0.84
Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus. Lupus (2005) 0.84
Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens (2000) 0.84
Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol (2002) 0.83
Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus (2001) 0.80
Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. Clin Rheumatol (2004) 0.80
Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum (2003) 0.79
Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus (2000) 0.78
Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study. Thromb Res (2001) 0.75
Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: relation to insulin resistance. J Rheumatol (2007) 0.83
Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2006) 0.82
Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. Clin Rheumatol (2004) 0.80
Methotrexate pneumonitis in a patient with rheumatoid arthritis. J Microbiol Immunol Infect (2003) 0.78
A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus. Clin Rheumatol (2006) 0.77
Assessment of wrist joint inflammation in patients with rheumatoid arthritis by quantitative two- and three-dimensional power Doppler ultrasonography. Clin Exp Rheumatol (2014) 0.77
Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis. J Clin Rheumatol (2022) 0.75